Incidence of psychiatric side effects during pegylated interferon-α retreatment in nonresponder hepatitis C virus-infected patients

Liver International

Volumn 27, Issue 8, 2007, Pages 1098-1102

  Quarantini, Lucas C ^a,b,c   Bressan, Rodrigo A ^b   Galvão, Amanda ^a   Batista Neves, Susana ^a   Paraná, Raymundo ^a   Miranda Scippa, Ângela ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Comorbidity; HepatitisC; Interferon; Psychiatricside effects; Retreatment

Indexed keywords

ALPHA INTERFERON; ALPRAZOLAM; ANTIVIRUS AGENT; MIRTAZAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; DELIRIUM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR DEPRESSION; MALE; MANIA; MENTAL DISEASE; NEUTROPENIA; PANIC; PSYCHOSIS; RETREATMENT;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANTIVIRAL AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PANIC DISORDER; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE;

EID: 34548628165     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01532.x     Document Type: Article

References (37)

1. Manns MP, Mchutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Steindl-Munda P, Ferenci P, Austrian Hepatitis Study group et al. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver Int 2003; 23: 269-75.
4. Boucher EJ, Jacquelinet S, Canva V, et al. High rate of long-term virological response after a 1-year course of interferon+/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial. Liver Int 2003; 23: 255-61.
5. Chuang WL, Dai CY, Chen SC, et al. Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. Liver Int 2004; 24: 595-602.
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (Suppl. 1): S237-44.
8. Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Neuropychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003; 25: 11-20.
9. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
10. Rifai MA, Bozorg B, Rosenstein DL. Interferon for hepatitis C patients with psychiatric disorders. Am J Psychiatry 2004; 161: 2331-2.
11. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156: 1120.
12. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-7.
13. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708-14.
14. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: A prospective study. Gen Hosp Psychiatry 2003; 25: 34-8.
15. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: Effect of interferon treatment. Dig Dis 2002; 20: 284-8.
16. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997; 26: 473-7.
17. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 2005; 66: 41-8.
18. Raber J, Koob GF, Bloom FE. Interferon-alpha and transforming growth factor-beta 1 regulate corticotrophin-releasing factor release from the amygdala: Comparison with the hypothalamic response. Neurochem Int 1997; 30: 455-63.
19. Owens MJ, Nemeroff CB. The role of corticotrophin-releasing-factor in the pathophysiology of affective and anxiety disorders: Laboratory and clinical studies. Ciba Found Symp 1993; 172: 296-308.
20. Dallman MF, Jones MT. Corticosteroid feedback control of ACTH secretion: effect of stress-induced corticosterone secretion on subsequent stress responses in the rat. Endocrinology 1973; 92: 1367-75.
21. Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFN-α): results from a prospective study. Eur Psychiatry 2006; 21: 204-10.
22. Amorim P. Mini International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr 2000; 22: 106-15.
23. Farber GA, Levin T, White CA. A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment. Gen Hosp Psychiatry 2005; 27: 329-37.
24. Pariante C, Orru M, Baita A, Farci M, Carpiniello B. Treatment with interferon-[alpha] in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 131-2.
25. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987; 147: 1577-80.
26. Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alpha-induced depression in patients with chronic hepatitis C. Hepatology 2002; 35: 978-9.
27. Mcdonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 1987; 21: 1175-8.
28. Parana R, Lyra L, Trepo C. Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil. Am J Gastroenterol 1999; 94: 857-8.
29. Conry-Cantilena C, Vanraden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 27: 1691-6.
30. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93: 785-9.
31. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB. Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients. World J Biol Psychiatry 2003; 4: 115-8.
32. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793-8.
33. Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12: 96-100.
34. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alpha therapy by the patient's initial affective state. N Engl J Med 1999; 29: 1370.
35. Quarantini LC, Miranda-Scippa A, Schinoni MI, et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: A randomized, controlled pilot study. Clin Neuropharmacol 2006; 29: 138-43.
36. Quarantini LC, Miranda-Scippa A, Paraná R, Sampaio AS, Bressan RA. Acute dystonia after injection of pegylated interferon alpha-2b. Mov Disord 2007; 22: 747-8.
37. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82: 175-90.